Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, Peterson BA, Byrd JC, Cheson BD; Cancer and Leukemia Group B Study 9153. Blum KA, et al. Among authors: cheson bd. Cancer. 2006 Dec 15;107(12):2817-25. doi: 10.1002/cncr.22344. Cancer. 2006. PMID: 17120198 Free article. Clinical Trial.
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).
Smith SM, Schöder H, Johnson JL, Jung SH, Bartlett NL, Cheson BD; Alliance for Clinical Trials in Oncology. Smith SM, et al. Among authors: cheson bd. Leuk Lymphoma. 2013 Jul;54(7):1405-10. doi: 10.3109/10428194.2012.744453. Epub 2013 Jan 4. Leuk Lymphoma. 2013. PMID: 23194022 Free PMC article. Clinical Trial.
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA; Alliance for Clinical Trials In Oncology (ACTION). Rizzieri DA, et al. Among authors: cheson bd. Br J Haematol. 2014 Apr;165(1):102-11. doi: 10.1111/bjh.12736. Epub 2014 Jan 15. Br J Haematol. 2014. PMID: 24428673 Free PMC article.
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
Blum KA, Polley MY, Jung SH, Dockter TJ, Anderson S, Hsi ED, Wagner-Johnston N, Christian B, Atkins J, Cheson BD, Leonard JP, Bartlett NL. Blum KA, et al. Among authors: cheson bd. Cancer. 2019 Oct 1;125(19):3378-3389. doi: 10.1002/cncr.32289. Epub 2019 Jun 7. Cancer. 2019. PMID: 31174236 Free PMC article. Clinical Trial.
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD; Cancer and Leukemia Group B. Smith SM, et al. Among authors: cheson bd. Br J Haematol. 2008 Feb;140(3):313-9. doi: 10.1111/j.1365-2141.2007.06937.x. Br J Haematol. 2008. PMID: 18217897 Free article. Clinical Trial.
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
Blum KA, Jung SH, Johnson JL, Lin TS, Hsi ED, Lucas DM, Byrd JC, Cheson BD, Bartlett NL; Cancer and Leukemia Group B. Blum KA, et al. Among authors: cheson bd. Ann Oncol. 2010 Nov;21(11):2246-2254. doi: 10.1093/annonc/mdq211. Epub 2010 Apr 27. Ann Oncol. 2010. PMID: 20423913 Free PMC article. Clinical Trial.
605 results